C. Blair

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
C. Blair, Christian Blair, Christiana Blair, Christiana J. Blair
Publication record
49 papers · 4,415 citations · H-index 20

PAPERS

High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence
20249 citationsauthor #6
Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis
20242 citationsauthor #8
Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing
20235 citationsauthor #22
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I
202226 citationsauthor #11
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age
202231 citationsauthor #9
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
202141 citationsauthor #9
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
202126 citationsauthor #11
629. High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in African American Adults with HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence
20210 citationsauthor #6
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
20201,201 citationsauthor #16
Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics
202024 citationsauthor #21
1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis
20206 citationsauthor #10
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
202057 citationsauthor #2
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
20201,102 citationsauthor #21
Remdesivir (GS-5734) is Efficacious in Cynomolgus Macaques Infected with Marburg Virus.
202065 citationsauthor #5
109. Preexisting Resistance and Week 48 Virologic Outcomes After Switching to B/F/TAF in African American Adults with HIV
20202 citationsauthor #5
73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
20200 citationsauthor #10
1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV
20202 citationsauthor #11
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.
201996 citationsauthor #12
OP0067 UTILITY OF RISK STRATIFICATION IN PREDICTING OUTCOMES OF INITIAL MONOTHERAPY VERSUS COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE: A POST-HOC ANALYSIS OF THE AMBITION STUDY
20190 citationsauthor #2
2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis
20193 citationsauthor #13
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
201928 citationsauthor #10
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
201916 citationsauthor #11
Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.
201817 citationsauthor #5
Early improvements predict outcomes in pulmonary arterial hypertension
20183 citationsauthor #3
Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial
20187 citationsauthor #2
Abstract 15437: A Phase 3 Single-Blind Study of Eleclazine in Subjects With Type 3 Long QT Syndrome
20170 citationsauthor #3
Baseline Predictors of Clinical Response: A Post Hoc Analysis of the Ambition Trial
20170 citationsauthor #2
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
201719 citationsauthor #6
Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial
201656 citationsauthor #4
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
20160 citationsauthor #10
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
201660 citationsauthor #15
Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
201630 citationsauthor #5
Advances in Clinical Trials Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy Designing the Late Sodium Current Inhibition With Eleclazine on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Trial
20160 citationsauthor #4
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population
20153 citationsauthor #10
OP0267 Initial Combination Therapy of Ambrisentan and Tadalafil in Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH): Subgroup Analysis from the Ambition Trial
20152 citationsauthor #11
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
2015171 citationsauthor #12
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
2015997 citationsauthor #14
Upfront Combination Therapy With Ambrisentan and TadalafilIin Treatment Naive Patients With Pulmonary Arterial Hypertension (PAH): Subgroup Analyses by Functional Class (FC), Etiology, and Region From the AMBITION Study
20142 citationsauthor #11
Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials
20147 citationsauthor #4
Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
201396 citationsauthor #5
Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
2013108 citationsauthor #2
152 Post-Marketing Hepatic Safety Profile of Ambrisentan in Patients with Pulmonary Arterial Hypertension – 4 Year Update
20125 citationsauthor #6
Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
201238 citationsauthor #6
57 ATHENA-1: Long Term Clinical Improvements Following the Addition of Ambrisentan to Background PDE5i Therapy in Patients with Pulmonary Arterial Hypertension
20125 citationsauthor #4
Does Treatment Response To Ambrisentan Vary By Pulmonary Arterial Hypertension Severity? Implications For Clinicians And For The Design Of Future Clinical Trials
20120 citationsauthor #4
ATHENA-1: Hemodynamic Improvements Following the Addition of Ambrisentan to Background PDE5i Therapy in Patients With Pulmonary Arterial Hypertension
201112 citationsauthor #7
Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension: 3-Year Outcome
201114 citationsauthor #3
mixed meal in type 2 diabetes Regulation of endogenous glucose production after a
20020 citationsauthor #13
Quantitative measures of neurological function in chronic neuromuscular diseases and ataxia.
198926 citationsauthor #5

TIMELINE

1989 26 citations

2002 0 citations

2011 26 citations

2012 48 citations

2013 204 citations

2014 9 citations

2015 1,173 citations

2016 146 citations

2017 19 citations

2018 27 citations

2019 143 citations

2020 2,459 citations

2021 67 citations

2022 57 citations

2023 5 citations

2024 11 citations

COAUTHOR MAP

CONCEPT FOOTPRINT